Design Therapeutics Inc DSGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $12.61
- Day Range
- $12.19–12.92
- 52-Week Range
- $3.76–17.25
- Bid/Ask
- $10.43 / $17.03
- Shares Outstanding
- 62.46M
- Market Cap
- $785.08M
- Volume/Avg
- 468,167 / 970,125
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 54
- Website
- https://www.designtx.com
Valuation
|
Metric
|
DSGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.60 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DSGN
|
|---|---|
Quick Ratio | 22.05 |
Current Ratio | 22.28 |
Interest Coverage | — |
Quick Ratio
DSGN
Profitability
|
Metric
|
DSGN
|
|---|---|
Return on Assets (Normalized) | −24.26% |
Return on Equity (Normalized) | −25.57% |
Return on Invested Capital (Normalized) | −29.51% |
Return on Assets
DSGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?Yr^ZqV | LOCK|pn&< | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|WgBKtC | LOCK|XM<X | $71B | |||
| argenx SE ADR
ARGX
| LOCK|$wd#wl% | LOCK|Rc | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?PX&hM^ | LOCK|N@ | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|l?JHyl | LOCK|^N?@ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&@%@jX? | LOCK|#S&sK | $26B | |||
| Moderna Inc
MRNA
| LOCK|<q!$<Y | LOCK|mPy | $25B | |||
| Incyte Corp
INCY
| LOCK|!t?yckD | LOCK|%&J | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|R^@LWRb | LOCK|?nD | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|wF$sQxJ | LOCK|&g$ | $16B |
United States